Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRC006
MIFTS: 55

Carcinoid Syndrome

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Carcinoid Syndrome

About this section

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 20 58 17 32
Carcinoid Tumor 20 17 70
Malignant Carcinoid Syndrome 58 70
Carcinoid Tumor No Icd-O Subtype 70
Carcinoid Tumor Syndrome 20
Carcinoid Tumors 42

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases Gastrointestinal diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare endocrine diseases


Sources

Summaries for Carcinoid Syndrome

About this section
GARD : 20 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face ( telangiectasias ), and wheezing. In later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure. The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. Only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. Treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms.

MalaCards based summary : Carcinoid Syndrome, also known as carcinoid tumor, is related to appendix carcinoid tumor and pulmonary blastoma. An important gene associated with Carcinoid Syndrome is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways are Neuroscience and HIF-1 signaling pathway. The drugs Lysine and Arginine have been mentioned in the context of this disorder. Affiliated tissues include appendix, heart and small intestine, and related phenotypes are night sweats and episodic abdominal pain

MedlinePlus : 42 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 73 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Sources

Related Diseases for Carcinoid Syndrome

About this section

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 819)
# Related Disease Score Top Affiliating Genes
1 appendix carcinoid tumor 32.1 SYP ENO2 CHGA
2 pulmonary blastoma 31.5 SYP SST CHGA CALCA
3 carcinoid tumors, intestinal 31.2 SYP SST MEN1 ENO2 CHGA
4 goblet cell carcinoid 31.1 ENO2 CHGA
5 atrophic gastritis 30.9 SST MEN1 CHGA
6 serotonin syndrome 30.8 SST PYY MEN1 IFNA2 HTR3A GHRH
7 horseshoe kidney 30.7 SYP ENO2 CHGA
8 conn's syndrome 30.6 SST MEN1 IGF1 CHGA CALCA
9 small cell carcinoma 30.6 SYP ENO2 CHGA CALCA
10 ectopic cushing syndrome 30.5 SST CHGA CALCA
11 benign teratoma 30.5 SYP ENO2 CHGA
12 lung benign neoplasm 30.4 SYP ENO2 CHGA
13 gastrinoma 30.4 SST MEN1 CHGA
14 appendix adenocarcinoma 30.4 SYP CHGA
15 pituitary tumors 30.3 SST MEN1 IGF1
16 ampulla of vater benign neoplasm 30.3 SYP SST ENO2 CHGA
17 large cell neuroendocrine carcinoma 30.3 SYP ENO2 CHGA
18 meckel diverticulum 30.2 SYP SST CHGA
19 small intestine neuroendocrine neoplasm 30.2 SST MEN1
20 pituitary adenoma 30.2 SST MEN1 IGF1 GHRH CHGA
21 glucagonoma 30.1 SST CHGA
22 mediastinal cancer 30.1 SYP ENO2 CHGA
23 pancreatic somatostatinoma 30.1 SST CALCA
24 tubular adenocarcinoma 30.1 SYP ENO2 CHGA
25 insulin-like growth factor i 30.0 SST IGF1 GHRH
26 diarrhea 30.0 SST PYY NTS IFNA2 HTR3A CALCA
27 acromegaly 30.0 SST MEN1 IGF1 GHRH
28 middle ear adenoma 30.0 SYP ENO2 CHGA
29 insulinoma 30.0 SST MEN1 CHGA
30 horner's syndrome 29.9 SDHD ENO2
31 hyperprolactinemia 29.9 SST IGF1 GHRH
32 rectum neuroendocrine neoplasm 29.9 SYP SST
33 hyperparathyroidism 29.9 MEN1 CHGA CALCA
34 hyperthyroidism 29.9 SST IGF1 CALCA
35 jejunal neoplasm 29.9 SYP ENO2
36 acth-secreting pituitary adenoma 29.9 SST MEN1 IGF1
37 mccune-albright syndrome 29.9 SST MEN1 IGF1
38 volvulus of midgut 29.8 SST PYY
39 leptin deficiency or dysfunction 29.8 PYY NPY IGF1 GHRH
40 hyperinsulinemic hypoglycemia 29.8 SST MEN1 ENO2
41 irritable bowel syndrome 29.8 SST PYY HTR3A CHGA
42 pulmonary sclerosing hemangioma 29.8 SYP ENO2 CHGA
43 neurofibromatosis, type i 29.7 SST SDHD MEN1 ENO2
44 multiple endocrine neoplasia 29.7 SST SDHD MEN1 CHGA CALCA
45 gangliocytoma 29.7 SYP GHRH ENO2
46 pituitary adenoma, prolactin-secreting 29.7 SST MEN1 IGF1 CHGA
47 thyroid carcinoma, familial medullary 29.7 SST MEN1 CHGA CALCA
48 teratoma 29.7 SYP SST ENO2 CHGA
49 cancer-associated retinopathy 29.7 VEGFA ENO2
50 zollinger-ellison syndrome 29.7 SST NTS MEN1 GHRH CHGA

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome
Sources

Symptoms & Phenotypes for Carcinoid Syndrome

About this section

Human phenotypes related to Carcinoid Syndrome:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 night sweats 58 31 frequent (33%) Frequent (79-30%) HP:0030166
2 episodic abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002574
3 intestinal carcinoid 58 31 frequent (33%) Frequent (79-30%) HP:0006723
4 erythematous plaque 58 31 frequent (33%) Frequent (79-30%) HP:0025474
5 protracted diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0004385
6 small intestine carcinoid 58 31 frequent (33%) Frequent (79-30%) HP:0006722
7 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
8 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
9 asthma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002099
10 tricuspid regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005180
11 facial telangiectasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007380
12 heart murmur 58 31 occasional (7.5%) Occasional (29-5%) HP:0030148
13 palpitations 58 31 occasional (7.5%) Occasional (29-5%) HP:0001962
14 epiphora 58 31 occasional (7.5%) Occasional (29-5%) HP:0009926
15 chronic noninfectious lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002730
16 right ventricular failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001708
17 increased serum serotonin 58 31 occasional (7.5%) Occasional (29-5%) HP:0003144
18 bronchospasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0025428
19 abnormal b-type natriuretic peptide level 58 31 occasional (7.5%) Occasional (29-5%) HP:0031138
20 rhinorrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0031417
21 myopathy 58 31 very rare (1%) Very rare (<4-1%) HP:0003198
22 paraganglioma 58 31 very rare (1%) Very rare (<4-1%) HP:0002668
23 hepatic necrosis 58 31 very rare (1%) Very rare (<4-1%) HP:0002605
24 lack of bowel sounds 58 31 very rare (1%) Very rare (<4-1%) HP:0030145
25 atypical pulmonary carcinoid tumor 58 31 very rare (1%) Very rare (<4-1%) HP:0030446
26 pulmonary carcinoid tumor 58 Occasional (29-5%)
27 carcinoid tumor 58 Obligate (100%)

MGI Mouse Phenotypes related to Carcinoid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.96 ENO2 GHRH HTR3A NPY NTS PYY
2 growth/size/body region MP:0005378 9.93 CHGA ENO2 GHRH HTR3A IGF1 MEN1
3 homeostasis/metabolism MP:0005376 9.7 CHGA GHRH HTR3A IGF1 MEN1 NPY
4 nervous system MP:0003631 9.44 CHGA ENO2 GHRH HTR3A IGF1 MEN1
Sources

Drugs & Therapeutics for Carcinoid Syndrome

About this section

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lysine Approved, Nutraceutical Phase 4 56-87-1 5962
2
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
3
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
4
Cyproheptadine Approved Phase 3 129-03-3 2913
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
7
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
8
leucovorin Approved Phase 2, Phase 3 58-05-9 6006
9
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 6857599 43805
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
11 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
12 Immunoglobulins Phase 3
13 Immunoglobulins, Intravenous Phase 3
14 Antibodies Phase 3
15 Antibodies, Monoclonal Phase 3
16 Mitogens Phase 3
17 Immunoglobulin G Phase 3
18 Endothelial Growth Factors Phase 3
19 Dermatologic Agents Phase 3
20 Anti-Allergic Agents Phase 3
21 Histamine Antagonists Phase 3
22
Histamine Phosphate Phase 3 51-74-1 65513
23 Histamine H1 Antagonists Phase 3
24 Immunosuppressive Agents Phase 2, Phase 3
25 Angiogenesis Inhibitors Phase 2, Phase 3
26 Micronutrients Phase 2, Phase 3
27 Antidotes Phase 2, Phase 3
28 Vitamin B9 Phase 2, Phase 3
29 Trace Elements Phase 2, Phase 3
30 Nutrients Phase 2, Phase 3
31 Vitamin B Complex Phase 2, Phase 3
32 Folate Phase 2, Phase 3
33 Protective Agents Phase 2, Phase 3
34 Vitamins Phase 2, Phase 3
35 Hormone Antagonists Phase 3
36 Neurotransmitter Agents Phase 3
37 5-hydroxytryptophan Phase 3
38 Serotonin Receptor Agonists Phase 3
39
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
40
Lactitol Approved, Investigational Phase 1, Phase 2 585-86-4 157355
41
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
42
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
45
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
46
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
47
Pancrelipase Approved, Investigational Phase 2 53608-75-6
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
50
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
2 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
5 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
6 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
7 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
8 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
9 A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues. Completed NCT00690430 Phase 3 Pasireotide;Octreotide
10 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Completed NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
11 Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
12 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
13 Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Not yet recruiting NCT04820751 Phase 3 Cyproheptadine Hydrochloride 4 MG
14 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
15 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
16 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
17 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Withdrawn NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
18 Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
19 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
20 A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
21 Dosimetry-Guided 90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC) Peptide Receptor Radiotherapy (PRRT) in Children & Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors Determined by 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) PET Unknown status NCT02441088 Phase 2 90Y-DOTA-tyr3-Octreotide;Aminosyn II
22 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
23 A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR® Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
24 Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors Completed NCT01396382 Phase 2
25 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
26 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
27 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
28 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
29 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
30 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
31 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
32 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
33 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
34 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
35 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
36 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Completed NCT02259725 Phase 2 regorafenib
37 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
38 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
39 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
40 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
41 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
42 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
43 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT02575300 Phase 2 Ibrutinib
44 An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
45 A Phase II Study of Axitinib in Advanced Carcinoid Tumors Completed NCT01435122 Phase 2 Axitinib
46 A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
47 EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
48 A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors Completed NCT00688623 Phase 2 Everolimus
49 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Completed NCT02441062 Phase 2 68Ga-DOTATOC PET/CT
50 A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00780663 Phase 2 Quarfloxin

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Interferon Alfa-2b
Sources

Genetic Tests for Carcinoid Syndrome

About this section
Sources

Anatomical Context for Carcinoid Syndrome

About this section

MalaCards organs/tissues related to Carcinoid Syndrome:

40
Appendix, Heart, Small Intestine, Ovary, Pituitary, Lung, Pancreas
Sources

Publications for Carcinoid Syndrome

About this section

Articles related to Carcinoid Syndrome:

(show top 50) (show all 5588)
# Title Authors PMID Year
1
Chromogranin A assessment in patients with neuroendocrine neoplasm of the small bowel and carcinoid syndrome treated with somatostatin analogues. 42 61
33269818 2020
2
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. 42
33370645 2021
3
Development and Validation of an Individualized Nomogram for Predicting Overall Survival in Patients With Typical Lung Carcinoid Tumors. 42
32889829 2020
4
Bilateral red choroidal metastases in a patient with a carcinoid tumor of the thymus. 61
33423813 2021
5
When POTS is the tip of the iceberg: Rare cases of dysautonomia as a possible manifestation of another disorder. 61
33459162 2021
6
DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT. 61
33795589 2021
7
Allergic contact dermatitis masquerading as carcinoid syndrome. 61
33089890 2021
8
Right sleeve S2 segmentectomy for lung carcinoid tumor in a patient with tracheal bronchus. 61
33025315 2021
9
Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival. 61
33239249 2021
10
Bronchial carcinoid with bronchocele masquerading as Scimitar syndrome on chest radiograph. 61
33488905 2021
11
Small Intestinal Hemangioma: A Case Report. 61
33774648 2021
12
Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops. 61
31587594 2021
13
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. 61
33776367 2021
14
Bronchial carcinoid tumor in the era of covid-19 pandemic: A case report. 61
33649715 2021
15
Carcinoid Heart Disease: a Review. 61
33725214 2021
16
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. 61
32146619 2021
17
Value of a patient-reported-outcome measure of carcinoid syndrome symptoms. 61
33690153 2021
18
Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study. 61
33382891 2021
19
Gallbladder Uptake Mimicking Liver Metastasis on 177Lu-DOTATATE Posttherapy Scan Gallbladder Uptake on 177Lu-DOTATATE Scan. 61
33512839 2021
20
Contributions of Adenocarcinoma and Carcinoid Tumors to Early-Onset Colorectal Cancer Incidence Rates in the United States. 61
33315473 2021
21
A rare case of multiple endocrine neoplasia type 1 initially presenting as an asymptomatic, huge mediastinal mass: case report. 61
33632163 2021
22
Catheter Ablation in Patients With Neuroendocrine (Carcinoid) Tumors and Carcinoid Heart Disease: Outcomes, Peri-Procedural Complications, and Management Strategies. 61
33602395 2021
23
68Ga-DOTATATE-avid pulmonary sclerosing pneumocytoma in a man of North African descent: Case report, imaging findings and pathology. 61
33725576 2021
24
Percutaneous Image-Guided Core Needle Biopsy of Neuroendocrine Tumors: How Common Is Intraprocedural Carcinoid Crisis? 61
33608193 2021
25
Heterogeneous tumor-immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti-PD-L1 antibody therapy. 61
33300302 2021
26
Huge typical pulmonary carcinoid presented with gigantism syndrome. 61
32725474 2021
27
Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review. 61
32172229 2021
28
Surgical Management of Primary Small Bowel NET Presenting Acutely with Obstruction or Perforation. 61
32696097 2021
29
Metastatic Carcinoid Tumor to Heart. 61
33342918 2021
30
The Outcome of Primary Hepatic Carcinoid Tumor: A Retrospective Study Based on Propensity Score Matched Survival Analysis. 61
33718162 2021
31
Middle Ear Carcinoid Tumor With External Auditory Canal Extension: A Case Report. 61
33470831 2021
32
Asymptomatic Ileal Neuroendocrine "Carcinoid" Tumor Incidentally Diagnosed on Colorectal Cancer Screening Colonoscopy: Does Routine TI Intubation Matter? 61
33623719 2021
33
Synchronous Upper Intestinal Neurofibromas and Duodenal Periampullary Well-Differentiated Neuroendocrine Tumor Associated With Neurofibromatosis 1. 61
32856931 2021
34
Pigmented spindle cell variant of a thymic atypical carcinoid in an octogenarian. 61
33409736 2021
35
Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review. 61
32097914 2021
36
Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management. 61
33070143 2021
37
Update in carcinoid heart disease - the heart of the matter. 61
33443717 2021
38
Primary cardiac low-grade neuroendocrine tumor: a case report and review of the literature. 61
33434636 2021
39
Rare Presentation of a Metastatic Pancreatic Neuroendocrine Neoplasm Presenting with Atrial Flutter. 61
33585343 2021
40
Recurrence of a neuroendocrine tumor of adrenal origin: a case report with more than a decade follow-up. 61
33413271 2021
41
Solitary myocardial metastasis from neuroendocrine tumor: surgical resection as curative surgery. 61
32556900 2021
42
Surgical Management of Neuroendocrine Tumor Liver Metastases. 61
33220808 2021
43
Perforated Carcinoid Tumor of the Appendix: Need for Guidelines for Management With Respect to Prognostic Factors. 61
33502242 2021
44
[Clinicopathological characteristics of goblet cell adenocarcinoma of the appendix]. 61
33396982 2021
45
[Clinical Course of Typical and Atypical Carcinoids (bpNET): Evaluation of PneuNET Register Berlin Data for the Identification of Indicators for Prognosis Determination and Therapy Planning]. 61
33461225 2021
46
An infertile female delivered a baby after removal of primary renal carcinoid tumor. 61
33542957 2021
47
De Garengeot Hernia Containing Acute Appendicitis and Carcinoid Tumor. 61
33522257 2021
48
Four synchronous primary tumors in a male patient. 61
33723165 2021
49
Expanding the Frontiers of Treatment: Cryoablation of an Ovarian Mass. 61
33575138 2021
50
Lutetium therapy-induced carcinoid crisis: A case report and review of literature. 61
33380679 2020
Sources

Variations for Carcinoid Syndrome

About this section
Sources

Expression for Carcinoid Syndrome

About this section
Search GEO for disease gene expression data for Carcinoid Syndrome.
Sources

Pathways for Carcinoid Syndrome

About this section

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.99 SYP NPY ENO2 CALCA
2
HIF-1 signaling pathway 36
11.17 VEGFA IGF1 ENO2
3
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
10.7 VEGFA SYP IGF1
4
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.56 PYY NPY
Sources

GO Terms for Carcinoid Syndrome

About this section

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA SST PYY NTS NPY IGF1
2 neuronal cell body GO:0043025 9.62 SST HTR3A ENO2 CALCA
3 terminal bouton GO:0043195 9.33 SYP GHRH CALCA
4 extracellular space GO:0005615 9.32 VEGFA SST PYY NPY IGF1 IFNA2
5 neuronal dense core vesicle GO:0098992 9.26 NPY CHGA

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.93 SST PYY NTS NPY GHRH CALCA
2 cell-cell signaling GO:0007267 9.56 SST IFNA2 GHRH CALCA
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 VEGFA IGF1 IFNA2
4 regulation of blood pressure GO:0008217 9.5 NPY CHGA CALCA
5 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 IGF1 GHRH
6 intestinal epithelial cell differentiation GO:0060575 9.4 PYY NPY
7 response to heat GO:0009408 9.33 SST IGF1 CALCA
8 feeding behavior GO:0007631 9.13 PYY NPY CALCA
9 neuropeptide signaling pathway GO:0007218 8.92 PYY NTS NPY CALCA

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.26 PYY NTS NPY GHRH
2 neuropeptide Y receptor binding GO:0031841 9.16 PYY NPY
3 hormone activity GO:0005179 9.1 SST PYY NPY IGF1 GHRH CALCA
Sources

Sources for Carcinoid Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....